| Description | Azadiradione (AZD) (AZD) from the methanolic extract of seeds of Azadirachta indica |
| In vitro | Azadiradione（AZD）在细胞和与多聚谷氨酸扩展疾病相关的果蝇模型中，显著缓解因蛋白聚集引起的毒性。这些效果与HSF1功能的激活及其目标蛋白质伴侣基因的表达相关。值得注意的是，AZD对HSF1的激活不依赖于细胞内HSP90或蛋白酶体功能。此外，我们证明AZD能够与纯化的人类HSF1直接高特异性互作，并促使HSF1与其识别序列的结合亲和力增强。这些独特发现使AZD成为针对影响全球数百万人的神经退行性疾病（NDs）药物开发的理想先导分子[1]。 |
| Synonyms | AZD |
| molecular weight | 450.57 |
| Molecular formula | C28H34O5 |
| CAS | 26241-51-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/ml (122.07 mM) |
| References | 1. Nelson V K , Ali A , Dutta N , et al. Azadiradione ameliorates polyglutamine expansion disease in Drosophila by potentiating DNA binding activity of heat shock factor 1[J]. Oncotarget, 2016, 7(48):78281-78296. 2. Singh, Kumar B , Vatsa, et al. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease[J]. Molecular Neurobiology, 2018. |